Naruo Yoshimura

Phase III Study of Docetaxel Compared With Vinorelbine in Elderly Patients With Advanced Non–Small-Cell Lung Cancer: Results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904)

Shinzoh Kudoh, Koji Takeda, Kazuhiko Nakagawa et al. · Journal of Clinical Oncology · 2006 · 365 citations · Full text

Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial

Kōichi Goto, Yuichiro Ohe, Taro Shibata et al. · The Lancet Oncology · 2016 · 147 citations

Second-line Treatment, Medicine, Randomised Phase 3 +9

EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib

Naruo Yoshimura, Shinzoh Kudoh, Tatsuo Kimura et al. · Lung Cancer · 2005 · 81 citations

Medicine, Receptor Tyrosine Kinase, Pathology +7

Phase II study of weekly paclitaxel for relapsed and refractory small cell lung cancer.

Nobuyuki Yamamoto, Junji Tsurutani, Naruo Yoshimura et al. · PubMed · 2006 · 75 citations

Refractory Sclc, Oncology, Refractory Cases +14

Phase II study of a combination regimen of gefitinib and pemetrexed as first-line treatment in patients with advanced non-small cell lung cancer harboring a sensitive EGFR mutation

Naruo Yoshimura, Shinzoh Kudoh, Shigeki Mitsuoka et al. · Lung Cancer · 2015 · 51 citations

Sensitive Egfr Mutation, Medicine, Combination Regimen +7